GLP-1 processing, such as Semaglutide (under the brands Ozempic and Wegovy) Novo Nordisk a/S NYSE: NVO Probably the hottest history of the medical sector in 2024. With his proposal Tirzepatide (corporate party as Mounjaro and Zepbound), Eli Lilly and Co. NYSE: Lly He was another key pharmaceutical player in this new type of treatment for diabetes and obesity. Revenue profit followed the popularity of these treatment methods. Eli Lilly saw how in the third quarter of 2024 sales to Maunjaro rising by 114% in annual calculus, largely defeating Novo Nordisk due to the presence of a sentence.
Eli Lilly and the company today
Eli Lilly and Company
- 52-week range
- $ 637.00
▼
$ 972.53
- Dividend yield
- 0.64%
- P/e ratio.
- 87.39
- Value is valuable
- $ 997,22
However, Eli Lilly shares have been random in recent months. Although the shares increased by 25.1% per year, leading before January 24, 2025, in the rear half of this period – six months from the end of July 2024 to January – Lly fell by more than 4%. This is all, despite the record price of shares, about $ 973, reached in 2024 for a sales of Tyrzepatide sales.
Investors can naturally wonder what is happening to Eli Lilly and what they can expect from a pharmaceutical giant in the future. In addition to the existing GLP-1 offers, Eli Lilly can contact investors for his Tirzepatide-to-and-in-law tablet in 2026, as well as for its oncological products. Indeed, the company’s pipeline is generally impressive.
What to expect from blockbusters GLP-1
Most of Eli Lilly’s impulse in recent quarters was associated with Munjaro and Zepbound. However, in January 2025The company updated its 2024 income leadership and offered a leadership for the New Year, which Many investors found disappointing. Sales are still flourishing-Chairman and CEO David A. Ricks said that the US innovation market (covering GLP-1 medicines) increased by 45% compared to last year until the last quarter of 2024. However, the company does not expect that sales of its two GLP-1 processings will grow as quickly as it was originally expected.
Investors may remember that Eli Lilly still predicts a significant increase in the highest level for 2024 and especially for 2025. The company expects an income of $ 45 billion for 2024 and somewhere in the range from 58 billion US dollars to $ 61 billion for 2025. Help in managing this growth. Is Eli Lilly agreed on the support of GLP-1 production. The company expects to produce in the first half of 2025, at least 60% more than in 2024.
There are even more reasons to be excited about the potential for Zepbound, in particular, in 2025 and older – in 2024, the FDA approved this drug for the treatment of obstructive approximate apnea (OSA) in adults with obesity. Zepbound is the first approved FDA treatment for OSA, which opens a new part of the market and gives Zepbound the potential advantage over other GLP-1, currently available.
New products to observe
Orforglipron is a version of Tyrzepatide Eli Lilly, and the company expects data on the experimental drug by the middle of this year and potential approval in the first few months of 2026. Considering that GLP-1 drugs currently require regular injection, this is most likely many patients will choose a simple tablet option if it will be sent. In addition, Eli Lilly has another candidate for GLP-1 in work, which seems the most powerful. It was shown that retratrutide brings the greatest weight loss for all GLP-1.
With the popularity of GLP-1 drugs, it is easy to forget that Eli Lilly also has a deep list of many other strong candidates. In particular, analysts prefer the oncological slate of the company, including Verzenio, the oral medicine used to treat certain types of breast cancer. Sales of only this drug reached almost $ 4 billion in the third quarter of 2024, an improvement by 38% compared to last year. In addition, Eli Lilly has a number of exciting oncological drugs in the work, including STX-478 from Scorpion Therapeutics, for which the company recently paid $ 2.5 billion.
All this suggests that, despite the huge success of GLP-1, Eli Lilly has many other reasons to inspire optimism among investors.
Before considering Eli Lilly and the company, you will want to hear it.
Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before the wider market wins … And Eli Lilly and the company were not on the list.
While Eli Lilly and the company currently has a “moderate purchase” rating among analysts, analysts with the highest rating believe that these five promotions are better buying.
View five shares here
Enter your email address, and we will send you a list of seven marketbeat shares and why their long -term prospects are very promising.
Get this free report